GlassScriptPhysician profile
Spencer Bachow
NPI 1669765525
$16,970.27
in general payments reported to CMS, 2019-2025
49 companies · $2,689 in 2025
The $2,689 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,884 · 2020: $2,136 · 2021: $657 · 2022: $608 · 2023: $4,143 · 2024: $4,854 · 2025: $2,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,470 · Food and Beverage: $4,850 · Honoraria: $1,245 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,470.00 |
| Food and Beverage | $4,850.19 |
| Honoraria | $1,245.00 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,709.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,489.35 | 2019-2025 | Opdivo, Krazati, Reblozyl |
| Glaxosmithkline, LLC. | $2,088.13 | 2020-2025 | Zejula, Jemperli, Shingrix |
| Lilly USA, LLC | $1,033.95 | 2019-2025 | Jaypirca, Retevmo |
| Janssen Biotech, INC. | $976.55 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals LP | $548.86 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Genzyme Corporation | $540.25 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $438.72 | 2019-2025 | |
| Abbvie INC. | $345.39 | 2019-2025 | Venclexta |
| Incyte Corporation | $328.86 | 2019-2025 | Jakafi, Zynyz |
| Genentech USA, INC. | $309.23 | 2019-2025 | Itovebi, Venclexta, Phesgo |
| Kite Pharma, INC. | $300.44 | 2022-2024 | Yescarta |
| Celgene Corporation | $297.84 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $268.56 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $227.36 | 2019-2025 | Xtandi, Padcev |
Show all 46 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Bachow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.